Preventing infection with Pseudomonas aeruginosa using novel non-antibiotic molecules

Name: Professor Phil Robinson
Partner Organisation: Royal Children’s Hospital
Project Start Date: January 1, 2025
THIS PROJECT IS NOW COMPLETE
Aims:
People with cystic fibrosis (CF) are at risk of lung function decline from persistent lung infection, particularly those caused by Pseudomonas aeruginosa, a bacterium that can be difficult to treat due to antibiotic resistance and protective layers formation. New strategies to prevent or delay infection are therefore urgently needed.
This project aimed to investigate whether natural carbohydrates, fucose and galactose (FG), could help prevent these bacteria from attaching to the airways. Using respiratory cells from people with CF in laboratory studies, the research explored whether these molecules can reduce bacteria colonisation and help prevent lung infections from developing.
Outcomes: The research team successfully recruited 15 adult with CF from the Royal Children’s Hospital and Monash Health. Preliminary analyses showed that treatment with FG significantly reduced the amount of bacteria attaching to airway cells. The treatment also helped preserve the movement of cilia, the tiny hair-like structures that help clear mucus and bacteria from the lungs. These findings suggest that FG treatment may help protect the airways against bacterial infection.
Research translation and Impact:
This study provided encouraging early evidence that FG treatment could help prevent Pseudomonas aeruginosa infections in people with CF. The results provide a strong foundation for developing the treatment further and support the planning of a future pilot clinical trial to assess its safety and potential benefits in people with CF. As a potential non-antibiotic approach, FG treatment could one day help reduce the need for antibiotics and contribute to efforts to combat antibiotic resistance.
